First quarter highlights
Delivered total first quarter revenue of $707 million, an increase of 11% on a reported and core revenue basis, including Screening revenue of $540 million and Precision Oncology revenue of $167 million
Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $40 million and $15 million, respectively
Launched the Cologuard Plus™ test, the company's next-generation colon cancer screening test
Presented data in the Journal of Surgical Oncology demonstrating the clinical strength of the Oncodetect™ test, the company’s molecular residual disease (“MRD”) and recurrence monitoring test
Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $40 million and $15 million, respectively
Launched the Cologuard Plus™ test, the company's next-generation colon cancer screening test
Presented data in the Journal of Surgical Oncology demonstrating the clinical strength of the Oncodetect™ test, the company’s molecular residual disease (“MRD”) and recurrence monitoring test
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.